Treatment of patients with Nodular lymphocyte predominant Hodgkin lymphoma at diagnosis can improve progression-free survival, compared to watchful waiting.

314 patients
82.5% had early-stage nodular lymphocyte predominant Hodgkin lymphoma

- Watchful waiting (36.3%)
- Radiotherapy (20.1%)
- Rituximab (8.9%)
- Chemotherapy or immuno-chemotherapy (21.7%)
- Combined modality treatment (12.7%)
- Radiotherapy and rituximab (0.3%)

Early treatment with chemotherapy or radiotherapy (but not rituximab alone) reduces the risk of progression ($p=0.0002$)

Lazarovici et al., Haematologica, 2015